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Homeobox genes are known to be critically important in tumor development and progression. The BP1 (Beta 
Protein 1) gene, an isoform of DLX4, belongs to the Distal-less (DLX) subfamily of homeobox genes and en-
codes a homeodomain-containing transcription factor. Our studies have shown that the BP1 gene was over-
expressed in 81% of primary breast cancer and its expression was closely correlated with the progression of 
breast cancer. However, the exact role of BP1 in breast has yet to be elucidated. Therefore, it is important to 
explore the potential transcriptional targets of BP1 via whole genome-scale screening. In this study, we used 
the chromatin immunoprecipitation on chip (ChIP-on-chip) and gene expression microarray assays to identify 
candidate target genes and gene networks, which are directly regulated by BP1 in ER negative (ER-) breast 
cancer cells. After rigorous bioinformatic and statistical analysis for both ChIP-on-chip and expression mi-
croarray gene lists, 18 overlapping genes were noted and verified. Those potential target genes are involved in a 
variety of tumorigenic pathways, which sheds light on the functional mechanisms of BP1 in breast cancer de-
velopment and progression. 
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1. Introduction 
BP1 (GenBank accession no.: AF254115) se-
quence analysis has revealed that it belongs to the 
Distal-less (DLX) subfamily of homeobox genes [1], 
which encodes a homeodomain-containing transcrip-
tion factor. BP1 is an isoform of DLX4, which has two 
functionally distinctive splice variants including 
DLX7 [2]. BP1 and DLX7 are apparent isoforms ex-
pressed either as splice variants transcribed from a 
single gene or driven by different promoters. The se-
quence similarity extends to nucleotide 565 of BP1 
where upstream sequences begin to diverge. Fur-
thermore, using FISH (Fluorescence In Situ Hybridi-
zation) and PCR, BP1 was mapped to chromosome 
17q21-22, the same region to which DLX7 was local-
ized [1].   
BP1 gene expression was absent or very low in 
normal mammary tissue, but was overexpressed in 
81% of primary breast cancer. In addition, BP1 was 
expressed in a series of breast cancer cell lines and 
high levels of BP1 expression in breast cancer cell 
lines strongly correlates with its tumorigenic potential 
[3]. BP1 expression was closely correlated with the 
progression of breast cancer [4]. Furthermore, in-
creased BP1 may impart a survival advantage to Int. J. Biol. Sci. 2009, 5 
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breast cancer cells, which could be a cause of thera-
peutic resistance in cancer treatment [5]. Through 
electrophoretic mobility shift assays (EMSA), 
site-directed mutagenesis and luciferase reporter as-
says, it was found that BP1 contributes to the inhibi-
tion of apoptosis in MCF7 breast cancer cells chal-
lenged with TNFα and that the bcl-2 gene is a direct 
target of BP1 protein [5].   
Therefore, experimental whole genome-scale 
screening is needed to unveil the potential target 
genes for BP1 homeoprotein. The recently developed 
protein-DNA binding assay technique, commonly 
named ChIP-on-chip, is able to produce comprehen-
sive genome-wide location information for specific 
transcription factors. Identifying the BP1 targets 
would provide new information of regulatory roles of 
BP1 in breast cancer and potential novel targets for 
early detection and intervention. But ChIP-on-chip 
based evidence for transcription factor binding does 
not always correlate with the actual transcriptional 
regulation of the target genes. Thus, we applied this 
method in conjunction with expression microarray 
and BP1 motif analysis of the promoter region, to 
identify candidate target genes that are directly regu-
lated by BP1 in breast cancer cell line Hs578T. The 
overall scheme is depicted in Figure 1. 
 
 
Figure 1. Overall experimental design scheme to identify targets of BP1 in Hs578T breast cancer cells. 
ChIP-on-chip was performed on BP1-overexpressing Hs578T cell lines, O6 and O7. Specific target genes were identified by 
comparing with IgG-pulled DNA. Affymetrix Human Genome Focus arrays were used to identify differentially expressed 
genes associated with BP1 overexpression using BP1 overexpressors, O6 and O7 and empty vector controls, V1 and V2. 
Overlapping target genes between ChIP-on-chip and expression array analysis were identified for further analysis. 
 
2. Materials and Methods 
2.1. Cell Culture / Cell Morphology and MTT 
assay 
Two Hs578T stable cell lines transfected with 
pcDNA3.2/BP1 (O6 and O7) were used, along with 
two controls containing vector pcDNA3.2-DEST alone 
(V1 and V2). Cells were maintained in DMEM sup-
plemented with 10% fetal bovine serum, penicil-
lin/streptomycin, 400μg/ml G418 antibiotics, and 
2mM glutamine. The BP1 expression level of mRNA 
and protein was confirmed by QPCR and Western 
Blot assay (Rabbit Polyclonal anti-BP1, NB100-481, 
NOVUS, Taiwan). 
In order to determine cell proliferation rate, the 
Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma, 
USA) metabolic assay was employed. Cells were 
seeded in a 24-well microplate at a concentration of 
10,000cells/well. The medium was changed at 12h. 
Survival was evaluated by replacing the culture me-
dia with 200μl of 0.5mg/ml MTT-media solution after 
24h, 48h and 72h incubation. The followed by 4h of Int. J. Biol. Sci. 2009, 5 
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incubation at 37ºC, the MTT reagent was removed 
before adding 200μl of DMSO. The absorbance was 
determined at 560 nm with a microplate reader (Mo-
lecular Devices).   
Cell images were taken by a Nikon Eclipse 
TE3000 inverted microscope with 40× and 100× mag-
nification (Nikon, Inc., Melville, NY) and MagnaFire 
software. For the ChIP-on-chip experiment, cells were 
cultured in a T-150 flask for 24h before harvest. 
2.2. Chromatin Immunoprecipitation (ChIP)  
The ChIP-on-chip experiments were performed 
on two BP1-overexpressing cell lines, O6 and O7. 
ChIP was carried out using the Upstate kit (New 
York, USA). The number of cells used was about 
5×107 for each sample. Protein-DNA cross-links were 
formed by incubating the cells in 1.42% (V/V) for-
maldehyde at room temperature for 15 min. Glycine 
was then added, yielding a final concentration of 
0.125M, for 5 min to stop the cross-linking. Sonication 
(Sonifier Cell Disrupter 350 model, Branson Ultra-
sonics Corporation, USA) was performed 11 times, 15 
seconds per sonication, to generate 200-500bp frag-
ments. The lysate was pre-cleared with a protein G/A 
beads (Calbiochem, USA) slurry for 2h. A 120 µg ali-
quot of the clear lysate was saved as an “input” con-
trol. The remaining lysate was split into 2 eppendorf 
tubes, and incubated individually with 15µg of spe-
cific antibody against BP1 (Rabbit Polyclonal 
anti-BP1, NB100-481, NOVUS, Taiwan) and 15µg of 
rabbit IgG (sc-2027, Santa Cruz, USA) at 4ºC over-
night. Next, salmon sperm DNA/protein G/A beads 
were added to each tube for 2h and the beads were 
pelleted, then eluted. Before phenol-chloroform DNA 
extraction, the protein-chromatin cross-linking was 
reversed by proteinase K for the immunoprecipitated 
samples and incubated at 65ºC overnight.   
2.3. Amplification and microarray assay 
The whole-genome amplification (WGA, Sigma) 
method was used to amplify sufficient amounts of 
DNA for hybridization to the promoter arrays. The 
standard protocol for WGA using the GenomePlex® 
WGA2 kit (Sigma-Aldrich, St. Louis, MO, USA) was 
adapted with modification of omitting the initial 
random fragmentation step because ChIP DNA sam-
ple is fragmented after sonication. A 10µl ChIP DNA 
samples (IgG and BP1) were amplified. The concen-
tration of the amplified DNA was detected by the 
nanodrop spectrophotometer. A total of 10.8µg of 
BP1-pulled DNA and 8.5 µg IgG-pulled DNA was 
amplified.  
The microarray chips used for ChIP analysis 
were GeneChip® Human Promoter 1.0R Array (Af-
fymetrix, USA). The fragmentation and labeling was 
performed with the GeneChip® Terminal Labeling Kit 
(Affymetrix, USA) according to the manufacturer’s 
recommendations. The final amount of DNA used in 
hybridization was 7.5µg for each sample. Four Ge-
neChip® Human Promoter 1.0R Array (Affymetrix, 
USA) chips were used for the analysis. The washing, 
staining, and scanning were performed as specified 
by the manufacturer, using the GeneChip® Hybridi-
zation Wash and Stain Kit, GeneChip® Hybridization 
Oven 640, GeneChip® Fluidics Station 450 and Ge-
neChip® Scanner 7G (Affymetrix, USA). 
2.4. Data analysis and verification  
Partek Genomics Suite 6.3 software was used to 
analyze the data. ChIP-on-chip CEL files were input 
into the software along with the following parame-
ters: segmentation parameter with three consecutive 
probes for minimum probe sets, 0.001 for P-value 
threshold, 1.5 for fold change and 0.5 for signal to 
noise. One-way ANOVA was used as the statistical 
method and Affymetrix U133 2.0 Plus Bed file was 
used to perform a region overlap. A total of 303 sig-
nificant enrichment binding sites, associated with 259 
relevant genes, between BP1 and IgG IP DNA were 
revealed. For the Human Genome Focused expres-
sion array analysis, the One-way ANOVA was used 
with the parameters of 0.001 for P-value threshold 
and 2 for fold change, resulting 306 differentially ex-
pressed genes. The overlap of the gene lists between 
the ChIP-on-chip and expression arrays is shown in 
Figure 4. 
To verify the accurate rate for the BP1 binding 
site that is shown in the ChIP-on-chip list, an inde-
pendent cell culture and ChIP assay were performed, 
in the same manner as described above. After pre-
cipitation and purification, 25µl dH2O was used to 
resolve the ChIP DNA. The 3µl of diluted input DNA 
(100 times dilution) and 3µl of ChIP DNA were used 
for PCR amplification, in order to verify BP1 binding 
sites in the IP DNA.   
Ten binding sites, whose target genes are rele-
vant to cancer, were selected for verification. RefSeq 
mapping data was collected from the UCSC Genome 
Browser’s RefFlat table (The UCSC genome browser 
database: update 2007). As previously described [6], 
the closest RefSeq 5` end for each ChIP region was 
identified, regardless of whether the cluster was up-
stream or downstream of the 5` end. The distance was 
calculated from the start of each cluster (Tab. 2 and 
Fig. 6). The Primer3 (v.0.4.0) was used to design the 
primers that amplifies the binding sites. At the same 
time, the target gene QPCR primers for mRNA ex-
pression analysis were designed to verify the mi-Int. J. Biol. Sci. 2009, 5 
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croarray results. The PCR results for ChIP DNA and 
QPCR results of gene expression were shown in Fig-
ure 6. 
2.5. Promoter Sequence, Gene Ontology and 
cascade analysis 
A motif-finding algorithm (MDScan) [7] was 
utilized to uncover motifs that are highly represented 
in the set of the promoter sequences. The logo pic-
tured in Figure 3 was generated by WEBLOGO 
(http://weblogo.berkeley.edu/logo.cgi). Functional 
categories were assigned using both the Genespring 
GX 9.0.5 (Agilent, USA) and manual inspection using 
the Gene Ontology (GO) (www.fatigo.org). In order 
to predict the relationship between BP1 direct targets 
and the cell character, Pathway Studio 5.0 (Ariadne, 
USA) was used to discover the cascades from BP1 
direct targets to indirect changed genes. 
3. Results   
3.1. Cell proliferation and morphology assay 
The BP1 transfected Hs578T cells were estab-
lished in our lab. The expression of BP1 mRNA was 
confirmed by QPCR and Western Blot assays (Fig. 2A, 
2B). After Hs578T cells were stably transfected by BP1, 
the cell proliferation ability was detected by the MTT 
assay. There was significantly more increasing prolif-
eration ability in BP1 transfected Hs578T cells than in 
vector transfected Hs578T cells (Fig. 2C). During the 
same time, it was ascertained the cell morphology in 
BP1 transfected Hs578T cells was changed. The cells 
became bigger, polygon, and had more antennae in 
BP1-overexpressing cells. The cells changed from a 
spindle form to a circular shape (Fig. 2D).   
 
 
 
 
Figure 2. Comparison of the expression, proliferation, and cell morphology between BP1 overexpressing 
cells and controls in Hs578T cells. (A) QPCR analysis of BP1 expression. BP1 mRNA was expressed more than 100 fold 
in O6 and O7 cells in comparison to the controls, V1 and V2 (P<0.01). (B) Western blot Analysis showing that BP1 protein 
levels are 5-fold higher in O6 and O7 cells than the controls, V1 and V2. β-actin was used as an internal control. (C) MTT 
assay for cell proliferation analysis. At 24h, 48h and 72h, the proliferation rate in O6 and O7 cells was significantly higher than 
that in V1 and V2 cells (P<0.01). The experiments were repeated 3 times. (D) The cell morphology analysis showing the 
difference between the O6, O7 (Circular) and V1, V2 cells (Spindle). Int. J. Biol. Sci. 2009, 5 
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3.2. ChIP-on-chip analysis of BP1 binding sites  
To identify targets of BP1 in an unbiased ge-
nome-wide manner, the Affymetrix GeneChip® Hu-
man Promoter 1.0R Array, containing the region 
spanning approximately 7.5kb upstream through 
2.45kb downstream of 5' transcription start sites of 
25,500 human genes, was employed. The 10kb tiling 
array around the transcription start site (TSS) was 
chosen because more and more evidence has shown 
the transcription factor bound to the big gap from TSS 
also modulates the gene expression [8-10]. 
In order to accurately locate the DNA binding 
sites of BP1, the experiment was performed with two 
BP1-overexpressing cell lines. A total of 153 promot-
ers (P<0.001), bound by BP1 in Hs578T cells (Supple-
mentary Table S1, which is published as supporting 
information on the web site), were identified. Binding 
by BP1 to a subset of targets was confirmed using 
conventional ChIP assays and PCR for 10 binding 
sites. The rate of false positives was <20% when pre-
viously established threshold criteria were used (Fig. 
6). The distance from binding start site to 5` transcrip-
tion start site was derived from the UCSC Genome 
Browser. The primers used in 10 binding sites are 
available online (Table 1).   
 
Table 1. Primers used for binding site identification and expression verification. 
Gene Symbol  Binding Site Identification  Expression Verification 
VEGFA  GAAGGTGCCCAGGTGAGAG  CTACCTCCACCATGCCAAGT 
  CAAATCTCTCCAGAGCCTCAA  GCAGTAGCTGCGCTGATAGA 
STAT1  TCTCACAAGAGGCTGGAGGT   CTTGTTGGGGCACAAGGT 
  GGCTCTGCTCGCCTACTCT  CCATGGGAAAACTGTCATCA 
EIF4E  TACAGTCGGGGAAGGAAGTG  TCGATCTAAGATGGCGACTG 
  ACAGAACTGACCAGAAACCATC  CTGGGTTAGCAACCTCCTGA 
MEIS1  TCTTTTCCCAGGCTGTCTTC  CATGGGAGGTTTCGTAATGG 
  TGATATCAATCATAGGTGTATAGCTCA  CCTTGCTTTGCGATTGGTTA 
MSR1  AGGGTGATGAGATGACAGAAA  TGCAGTTCTCATCCCTCTCA 
  TCAAGGTTAATTTGTTGGGAAC  CCTTTTCCCGTGAGACTTTG 
ITGA9  GAGCTCAAAAGTGCCCTCTC GAAGACCGCGATGATGAGT 
  TGAGGGAGGAAAAAGAAGCA GGATGTGGTCGGCTTCATAG 
HPSE2  GGCAAGTTGGATCGGAGTTA GGCCCGGATTACTATCTCAA 
  CGCAGGAGATTTAAGGAGGA GGAGCTCCAGCATAACATCAG 
IL2RA  CATGTGGTGCCAGCGTATAG CCACAGAAATGCAAAGTCCA 
  GACGCTCACAGTCTCCTCAA CCCCACCACGAAATGATAAA 
LAPTM5  ACCAGCTGTGTGTCTTGCAG CTGATCTCCAGCTTCCTGCT 
  TCCTGTCCTTTAAACCCTTTCTC CCATGATTTGCAGGGACAG 
MMP27  TTCCAGTCAGGCCAGATTTC CCCTGGGTGGAGAAAATACA 
  GCTCTGGGTTTTGGAGAATG TTGCTCCACACTTCTAAACCTC 
 
 
The results of the genome location experiment of 
BP1 were further analyzed using a motif-finding al-
gorithm (MDscan), which examines the ChIP-on-chip 
selected sequences and searches for DNA sequence 
motifs representing the protein–DNA interaction sites 
[7]. The consensus sequence derived from the most 
frequent motifs found in the BP1-bound promoters 
corresponds to a perfect BP1 response element 
(G/C)CTGCATG(T/C), which is visually represented 
in Figure 3. This sequence will be used to predict the 
binding site of BP1 protein in the genome. 
 
 
Figure 3. Genome-wide location analysis of direct 
BP1 transcriptional targets in Hs578T breast can-
cer cells. Motif-finding algorithms identify the consensus 
BP1 sequence (G/C)CTGCATG(T/C) as the most common 
transcription factor-binding motif, which presents in 60% of 
the promoters used for the analysis.   Int. J. Biol. Sci. 2009, 5 
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3.3. Gene expression microarray analysis  
The gene expression microarray assay was per-
formed to generate a differentially expressed gene list 
to identify the potential targets in common with that 
from the ChIP-on-chip assays. Levels of mRNA ex-
pression for each target were compared between vec-
tor transfected Hs578T cells and BP1 transfected 
Hs578T cells. The data from the Human Genome Fo-
cused arrays were analyzed using the Partek with 
strict thresholds (p<0.01, Foldchange>2). The result-
ing 306 differentially expressed genes were intensely 
analyzed by Gene Ontology. Because our experiment 
was performed in cancer cells, the focus was on cel-
lular physiological processes (GO: 50875). According 
to the biology function classification, 42 of 306 genes 
were associated with apoptosis, 32 were related to cell 
cycle progress, and 17 were involved in cell migra-
tion. It was shown that the mechanism of BP1 en-
hancing proliferation maybe because BP1 effects the 
apoptotic factors [2]. 
 
 
Figure 4. Pie chart representing major biological functions and processes associated with BP1 overexpres-
sion. The resulting 306 differentially expressed genes were intensely analyzed by Gene Ontology. In cellular physiological 
process classification, the major part was apoptosis followed by cell motility, cell cycle, cell-cell signaling, cell adhesion, cell 
migration, transcription regulator activity, morphogenesis, and cell growth. 
 
 
 
 
Figure 5. Venn Diagram showing the overlapping genes between gene lists from BP1 ChIPon-chip and ex-
pression microarray. Of 171 genes from the BP1 ChIP-on-chip data and the 306 genes that were differentially expressed, 
there were 18 of them overlapping. The intersecting region represents 18 genes whose promoter region may be bound by 
BP1 and that are deregulated when BP1 is overexpressed. Int. J. Biol. Sci. 2009, 5 
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3.4. Identification of direct gene targets that 
are expressed significantly different when BP1 
is overexpressed. 
To elucidate which gene BP1 binds to and de-
regulates, the Venn Diagram analysis through Partek 
was performed. There were 18 overlapping genes. 
The list for these 18 genes is shown in Table 2. The 
distance in the table represents the number of bases 
that use 5` transcription start site of the gene minus 
the binding start site. If this number is positive, the 
binding site is in front of the TSS, possibly in the 
promoter or enhancer region. If it is negative, the 
binding site maybe in the intron or exon of the target 
gene. 
 
 
Table 2. Overlapping genes between BP1 ChIP-on-chip data and the microarray results 
Gene Symbol  GenBank ID  Binding Site 
Distance (bp) 
Fold Change  Gene Function 
ADAM21  NM_003813 4280  -2.12012  proteolysis 
CASQ1  NM_001231 3641  -1.77249  mitochondrion 
CBR1  NM_001757  2651  -2.15584  carbonyl reductase (NADPH) activity 
CCL4  NM_002984  -13867  -1.78511  cell adhesion 
CSF2RB  NM_000395  -690  -2.24506  signal transduction 
HPSE2  NM_021828  -1075  -1.53345  hydrolase activity 
HTR1B  NM_000863  2552  -2.0201  signal transduction 
IL2RA  NM_000417  6214  -2.42635  positive regulation of apoptosis 
ITGA9  NM_002207  -2198  3.26587  Cell adhesion 
LAPTM5  NM_006762 3836  -2.24236  integral to plasma membrane 
LGALS13  NM_013268  -248  -1.93361  lipid degradation 
LSM7  NM_016199  -3962  2.32186  mRNA metabolism 
MMP27  NM_022122 600  -1.53542  proteinaceous extracellular matrix 
OR1A1  NM_014565 504  -2.81835  signal transduction 
PTPRE  NM_006504  -137517  -1.79625  protein amino acid dephosphorylation 
SELE  NM_000450  1369  -1.61012  cell adhesion 
TAC3  NM_013251  31955  -1.68822  neuropeptide signaling pathway 
VEGFA  NM_001025370  -3313  2.55763  angiogenesis, differentiation 
* Distance was calculated between the positions of 5` transcription start site and potential binding site, which were obtained from UCSC 
Genome Browser. Positive numbers signify the binding sites are in front of the TSS, and negative ones indicate they are located in the exon or 
intron regions. 
 
 
3.5. Verification by ChIP and QPCR 
Since the amount of genomic DNA obtained 
from the ChIP is limited, amplification is essential to 
generate sufficient DNA for microarray hybridiza-
tion. The method previously used was random 
primer amplification, which is recommended by Af-
fymetrix 
(http://www.affymetrix.com/products/arrays/speci
fic/human_promoter.affx). The method chosen in this 
study was WGA (Whole Genome Amplification). 
There are many labs now using this method and re-
porting very consistent data with low bias effects, and 
large quantities of DNA produced [11].   
To verify the potential binding sites from the 
ChIP-on-chip data, PCR was performed using prim-
ers flanking the region of interest; QPCR was also 
used for the verification of the microarray expression 
data. Ten sets of primers were designed for both 
ChIP-on-chip and expression analysis using the 
Primer3 (v.0.4.0). The UCSC Genome Browser analy-
sis for binding sites prediction, PCR binding site veri-
fication and the corresponding QPCR expression 
analysis is shown in Figure 6. In those 10 conven-
tional ChIP assays, 9 of them were consistent to the 
ChIP-on-chip assay. The data for ITGA9 shows the 
same level of DNA recruitment in both BP1 and IgG 
immunoprecipitated samples, which suggest there 
might be a weak binding. The QPCR showed all of 
them had the same gene expression trend as the gene 
expression array.   
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Figure 6. Schematic representations of the enrichment analysis and experimental verification of target 
genes. For each composite figure, left panel indicates the enrichment analysis using UCSC Genome Browser. The red peaks 
represent the enrichment of DNA immunoprecipitated with BP1 antibody, while the blue peaks represent that with the IgG 
antibody from the BP1 transfected Hs578T cells. The binding sites are indicated with arrows. Upper right agarose gel picture 
is the PCR amplification of a specific genomic region for binding site verification using BP1 and IgG immunoprecipitated DNA 
as template, with input DNA as a positive control. Lower right graph represents quantitative mRNA expression comparison 
between BP1-overexpressing cells, O6, O7 and V1, V2 by real-time RT-PCR. 
 
 
 
3.6. Pathway analysis 
Pathway Studio 5.0 was used to extensively 
analyze the data from both promoter and expression 
arrays. It is found that multiple differentially ex-
pressed genes from the expression array analysis are 
the targets of the genes that are directly regulated by 
BP1. Logically, it is believed that the reason BP1 in-
duces cell proliferation and enhances tumor metasta-
s i s  i s  t h e  r e s u l t  o f  d i r e c t  o r  i n d i r e c t  d o w n s t r e a m  
regulation. The cascade between VEGFA 
up-regulation and cell proliferation was shown in 
Figure 7.   
 Int. J. Biol. Sci. 2009, 5 
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Figure 7. Cascade between VEGFA, a direct target of BP1, and its downstream target genes in cell prolif-
eration. VEGFA functional cascades were analyzed by the Pathway Studio 5.0. Genes in the network, red for upregulated 
and green for down-regulated ones, are the targets of VEGFA, which collectively promote cell proliferation. 
 
4. Discussion 
Breast cancer is one of the most common malig-
nancies affecting women and is expected to be diag-
nosed in approximately 184,450 cases in the United 
States in 2008, and about 40,480 women will die from 
the disease this year alone [12]. Homeobox genes are 
known to be critically important in the normal de-
velopment of organisms from Drosophila to humans 
[13]; and cancer is a consequence of normal develop-
ment gone awry. It is logical to hypothesize that ab-
errant expression of these genes may contribute to 
cancer [14]. Actually, a lot of evidence has shown 
homeobox genes that are upregulated in cancer nor-
mally show expression patterns that are restricted to 
undifferentiated or proliferative cells [15]. Con-
versely, homeobox genes that are downregulated in 
cancer are normally expressed in differentiated tis-
sues. Homeobox genes can be re-expressed in the 
tumorigenic cells that are derivatives of embryonic 
cells in which the particular homeobox gene is nor-
mally expressed during development [16].  
The deregulated expression of homeobox genes 
has been described in many solid tumors and deriva-
tive cell lines. Among these, HOX, HSIX1, PAX have 
been shown to promote cellular transformation in 
breast cancer[17-19]. The human homologue HOXA1 
has been detected in breast cancer lesions and adja-
cent tissues [20]. HOXA1 mRNA expression is also 
modulated by retinoic acid, a common differentiation 
agent in MCF7 cells [21]. In addition, overexpression 
of murine Hoxb7 in SkBr3 breast adenocarcinoma 
cells caused increased proliferation and decreased 
growth factor dependency [22]. 
It was previously shown that the BP1 gene was 
overexpressed in 81% of primary breast cancer [3] 
and was closely correlated with the progression of 
breast cancer [4]. Furthermore, in order to elucidate 
the mechanism of BP1 function, it was discovered 
that the bcl-2 gene is a direct target of BP1 protein in 
MCF-7 cells, and contribute to the inhibition of apop-
tosis challenged with TNFα [5]. Our previous studies 
have shown that overexpression of BP1 presents a 
more aggressive phenotype in breast cancer cells 
(unpublished). The reasons for choosing the Hs578T 
cell line as a model are because: 1) Hs578T cells are 
estragon-receptor(ER) negative. There are no effective 
treatments for ER- breast cancer and often the prog-
nosis is poor; 2) Hs578T cell line expressed low or 
barely detectable BP1 [3]. Therefore, it is important to 
identify potential downstream targets of BP1 to elu-
cidate its biological functions in breast tumorigenesis 
and progression. Homeobox genes usually work as 
vital genes in embryogenesis and development [23]. 
Due to the fact that homeobox genes encode 
transcription factors which typically switch on cas-
cades of other genes, and that BP1 belongs to the DLX 
family of homeobox genes, it is believed that BP1 
regulates its target genes via direct binding to its cor-Int. J. Biol. Sci. 2009, 5 
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responding promoter or enhancer. Hence, the 
ChIP-on-chip strategy was used to identify the poten-
tial binding targets for BP1 homeoprotein.   
The antibody is one of the most important fac-
tors for the ChIP-on-chip experiment. Western blot 
was performed on the ChIPed lysate to verify the 
specificity of BP1 immunoprecipitation. The result of 
the Western Blot showed BP1 protein was bound by 
this particular BP1 antibody not only in vivo and but 
also following formaldehyde treatment. Therefore, 
we believe this antibody is suitable for the identifica-
tion of BP1 target genes.   
The accuracy rate of microarray data depends on 
the threshold chosen for the analysis. Although the p 
value in our analysis was 0.001, we can still identify 
10 potential binding sites, of which 9 of them were 
verified by a conventional ChIP assay. Therefore, the 
false positives rate was 10% using our threshold crite-
ria (see Materials and Methods). False positives can 
occur for a number of reasons in ChIP-on-chip ex-
periments. Therefore, it is recommended to perform 
independent ChIP experiments when ChIP-on-chip 
results are intended for further analysis.   
New target genes, within the functional catego-
ries, that are involved in cell proliferation and other 
important functions of cancer were identified. Given 
the known property of BP1 to stimulate cell prolifera-
tion and change cell morphology, it was surprising 
that only a few key genes were obtained in our loca-
tion analysis, for example, VEGFA and HPSE2.   
Binding of BP1 to the promoter regions of target 
genes is a vital step of BP1 function as a transcription 
factor. However, the binding of BP1 in the promoter 
region may not necessarily function as a transcrip-
tional activator or repressor depending on the mo-
lecular context. By comparing the expression mi-
croarray and binding sites target gene lists, 18 over-
lapping genes were obtained. Interestingly, most of 
these genes were down-regulated by BP1, showing 
that BP1 works as an inhibitor in most situations. Due 
to our luciferase assay system not working well with 
down-regulated genes, they could be a subject of fu-
ture study using a more amenable reading system. 
Many predictions can be generated from the es-
tablished VEGFA cascade network. For example, BP1 
directly up-regulates VEGFA expression according to 
ChIP and QPCR assay (Fig. 6). As reported previ-
ously, VEGF enhances the expression of ID [24], 
which can promote cell proliferation[24-27]. VEGF 
and ID1 both induce EPHA2 expression[27, 28], 
which also promote cell proliferation[29, 30]. This 
demonstrates that BP1 is an upstream regulator in the 
VEGF pathway.   
Despite the stringency of the integrated analysis 
of ChIP-on-chip and microarray data, we found a 
number of novel BP1 target genes, some of which are 
vital to cell proliferation and tumorigenesis. Of note, 
further analysis of the BP1 regulatory networks in 
tumorigenesis is warranted. Take note that the gene 
expression microarrays used only represent about 
9,000 genes, therefore whole genome arrays for gene 
expression and higher density tiling arrays for 
ChIP-on-chip assays would permit comprehensive 
target gene screening. Furthermore, BP1, as a homeo-
protein, it may not affect the gene expression for 
some targets by itself alone, which is probably why 
the expression of ITGA9 was not changed even 
though there is clear evidence that BP1 binds to its 
promoter.   
The results of these studies provide new infor-
mation of regulatory roles of BP1 in breast cancer and 
potential new targets for early detection and inter-
vention, which call for in depth research using patient 
samples for biomarker and new drug discovery.   
Abbreviations 
DLX: Distal-less gene; BP1: Beta Protein 1; ER: 
Estrogen Receptor; ChIP: Chromatin Immunopre-
cipitation; EMSA: Electrophoretic Mobility Shift As-
say; QPCR: Quantitative Polymerase Chain Reaction; 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide; WGA: Genome-wide Amplification; 
TSS: Transcription Start Site. 
Acknowledgements 
This work was supported by NIH grant 
CA102928 (SWF) and the McCormick Genomics 
Grant (SWF). The authors would like to thank Dr. 
Allan L. Goldstein for his support and the technical 
assistance from the Genomics Core Facility at GW. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.   Chase MB, Fu S, Haga SB, Davenport G, Stevenson H, Do K ,et 
al. BP1, a homeodomain-containing isoform of DLX4, represses 
the beta-globin gene. Mol Cell Biol. 2002; 22:2505-2514 
2.   Fu S, Stevenson H, Strovel JW, Haga SB, Stamberg J, Do K ,et al. 
Distinct functions of two isoforms of a homeobox gene, BP1 and 
DLX7, in the regulation of the beta-globin gene. Gene. 2001; 
278:131-139 
3.  Fu SW, Schwartz A, Stevenson H, Pinzone JJ, Davenport GJ, 
Orenstein JM ,et al. Correlation of expression of BP1, a ho-
meobox gene, with estrogen receptor status in breast cancer. 
Breast Cancer Res. 2003; 5:R82-87 
4.   Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. 
Expression of BP1, a novel homeobox gene, correlates with Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
12
breast cancer progression and invasion. Breast Cancer Res 
Treat. 2005; 90:241-247 
5.    Stevenson HS, Fu SW, Pinzone JJ, Rheey J, Simmens SJ, Berg PE. 
BP1 transcriptionally activates bcl-2 and inhibits TNFal-
pha-induced cell death in MCF7 breast cancer cells. Breast 
Cancer Res. 2007; 9:R60 
6.   Gao H, Falt S, Sandelin A, Gustafsson JA, Dahlman-Wright K. 
Genome-wide identification of estrogen receptor alpha-binding 
sites in mouse liver. Mol Endocrinol. 2008; 22:10-22 
7.  Liu XS, Brutlag DL, Liu JS. An algorithm for finding pro-
tein-DNA binding sites with applications to chroma-
tin-immunoprecipitation microarray experiments. Nat. Bio-
technol. 2002; 20:835-839 
8.  Melnikova L, Biryukova I, Kan T, Georgiev P. Long-distance 
interactions between regulatory elements are suppressed at the 
end of a terminally deficient chromosome in Drosophila 
melanogaster. Chromosoma. 2008; 117:41-50 
9.  Sipos L, Gyurkovics H. Long-distance interactions between 
enhancers and promoters. FEBS J. 2005; 272:3253-3259 
10.   Spirito F, Bossi L. Long-distance effect of downstream tran-
scription on activity of the supercoiling-sensitive leu-500 pro-
moter in a topA mutant of Salmonella typhimurium. J Bacterio. 
1996; 178:7129-7137 
11.   O'Geen H, Nicolet CM, Blahnik K, Green R, Farnham PJ. Com-
parison of sample preparation methods for ChIP-chip assays. 
BioTechniques. 2006; 41:577-580. 
12.  [Internet] American Cancer Society. http://www.cancer.org/ 
downloads/STT/2008CAFFfinalsecured.pdf.  
13.   Krumlauf R. Hox genes in vertebrate development. Cell. 1994; 
78:191-201. 
14.   Abate-Shen C. Deregulated homeobox gene expression in can-
cer: cause or consequence? Nat Rev Cancer. 2002; 2:777-785 
15.   Nunes FD, de Almeida FC, Tucci R, de Sousa SC. Homeobox 
genes: a molecular link between development and cancer. 
Pesqui Odontol Bras. 2003; 17:94-98 
16.   van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, 
Dorssers LC. Ectopic expression of epidermal growth factor 
receptors induces hormone independence in ZR-75-1 human 
breast cancer cells. Cancer Res. 1992; 52:5082-5088 
17.   Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. Ab-
rogation of the G2 cell cycle checkpoint associated with over-
expression of HSIX1: a possible mechanism of breast carcino-
genesis. Proc Natl Acad Sci U S A. 1998; 95:12608-12613. 
18.   Peverali FA, D'Esposito M, Acampora D, Bunone G, Negri M, 
Faiella A ,et al. Expression of HOX homeogenes in human 
neuroblastoma cell culture lines. Differentiation. 1990; 45:61-69 
19.   Silberstein GB, Van Horn K, Hrabeta-Robinson E, Compton J. 
Estrogen-triggered delays in mammary gland gene expression 
during the estrous cycle: evidence for a novel timing system. 
Journal Endocrinol. 2006; 190:225-239 
20.   Chariot A, Castronovo V. Detection of HOXA1 expression in 
human breast cancer. Biochem Biophys Res Commun. 1996; 
222:292-297 
21.   Chariot A, Moreau L, Senterre G, Sobel ME, Castronovo V. 
Retinoic acid induces three newly cloned HOXA1 transcripts in 
MCF7 breast cancer cells. Biochem Biophys Res Commun. 1995; 
215:713-720 
22.  Care A, Silvani A, Meccia E, Mattia G, Peschle C, Colombo MP. 
Transduction of the SkBr3 breast carcinoma cell line with the 
HOXB7 gene induces bFGF expression, increases cell prolifera-
tion and reduces growth factor dependence. Oncogene. 1998; 
16:3285-3289. 
23.   Boncinelli E. Homeobox genes in development. Adv Neurol. 
1999; 79:81-94 
24.   Sakurai D, Tsuchiya N, Yamaguchi A, Okaji Y, Tsuno NH, 
Kobata T ,et al. Crucial role of inhibitor of DNA bind-
ing/differentiation in the vascular endothelial growth fac-
tor-induced activation and angiogenic processes of human en-
dothelial cells. J Immunol. 2004; 173:5801-5809 
25.   Chaudhary J, Sadler-Riggleman I, Ague JM, Skinner MK. The 
helix-loop-helix inhibitor of differentiation (ID) proteins induce 
post-mitotic terminally differentiated Sertoli cells to re-enter the 
cell cycle and proliferate. Biol Reprod. 2005; 72:1205-1217 
26.   Harper EG, Alvares SM, Carter WG. Wounding activates p38 
map kinase and activation transcription factor 3 in leading 
keratinocytes. J Cell Sci. 2005; 118:3471-3485 
27.   Straume O, Akslen LA. Strong expression of ID1 protein is 
associated with decreased survival, increased expression of 
ephrin-A1/EPHA2, and reduced thrombospondin-1 in malig-
nant melanoma. Br J Cancer. 2005; 93:933-938 
28.   Jiang P, Li JH, Luo GQ, Liu J. [Effect of EphA2 protein on the 
expression of VEGF and MMP9 proteins in HCT116 cells]. 
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007; 32:679-683 
29.  Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L ,et al. A 
genome-wide screen reveals functional gene clusters in the 
cancer genome and identifies EphA2 as a mitogen in glioblas-
toma. Cancer Res. 2006; 66:10815-10823 
30.  Nasreen N, Mohammed KA, Antony VB. Silencing the receptor 
EphA2 suppresses the growth and haptotaxis of malignant 
mesothelioma cells. Cancer. 2006; 107:2425-2435 
 